Actinium Pharmaceuticals Inc. (ATNM) Downgraded to “Hold” at Zacks Investment Research
Actinium Pharmaceuticals Inc. (NYSEMKT:ATNM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Tuesday.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
A number of other brokerages have also commented on ATNM. Roth Capital assumed coverage on Actinium Pharmaceuticals in a research note on Thursday, August 25th. They issued a “buy” rating and a $5.00 price target for the company. FBR & Co set a $9.00 price target on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 21st.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/actinium-pharmaceuticals-inc-atnm-downgraded-to-hold-at-zacks-investment-research.html
Actinium Pharmaceuticals (NYSEMKT:ATNM) traded down 5.62% during mid-day trading on Tuesday, hitting $1.14. 843,535 shares of the stock traded hands. Actinium Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $3.50. The firm’s 50-day moving average is $1.64 and its 200 day moving average is $1.77. The firm’s market cap is $54.40 million.
In other Actinium Pharmaceuticals news, major shareholder Sloan-Kettering Cance Memorial sold 192,927 shares of the firm’s stock in a transaction on Wednesday, August 31st. The stock was sold at an average price of $1.83, for a total transaction of $353,056.41. Following the completion of the transaction, the insider now owns 4,878,988 shares of the company’s stock, valued at $8,928,548.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
A number of institutional investors have recently made changes to their positions in ATNM. BlackRock Institutional Trust Company N.A. raised its position in shares of Actinium Pharmaceuticals by 11.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 462,683 shares of the company’s stock valued at $819,000 after buying an additional 47,131 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Actinium Pharmaceuticals by 31.5% in the second quarter. BlackRock Fund Advisors now owns 102,003 shares of the company’s stock valued at $181,000 after buying an additional 24,453 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Actinium Pharmaceuticals by 19.2% in the second quarter. Vanguard Group Inc. now owns 1,581,228 shares of the company’s stock valued at $2,798,000 after buying an additional 254,318 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Actinium Pharmaceuticals during the second quarter valued at approximately $247,000.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.